Login to Your Account

Other News To Note

Wednesday, August 1, 2012
• Antisense Pharma GmbH, of Regensburg, Germany said it has been granted orphan drug designation from the FDA for its oncology antisense compound trabedersen to treat malignant melanoma. Previously, trabedersen has received orphan drug designation by the European EMA and the FDA in high-grade glioma (malignant brain tumor) and in advanced pancreatic cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription